Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Marnac, Inc.
Hyperfine Says Question Is When, Not If, Portable MRI Will Impact The World; CEO Dave Scott Discusses
Hyperfine, which markets the first US FDA-cleared portable MRI system, is facing COVID-related headwinds in bringing its system to hospitals, but CEO Dave Scott says wider adoption of the disruptive solution is inevitable. The company is going public today after combining with the HealthCor Catalio Acquisition Corp.
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.
An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.
Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.